TrialClinical and translational science2017

Leveraging a Clinical Phase Ib Proof-of-Concept Study for the GPR40 Agonist MK-8666 in Patients With Type 2 Diabetes for Model-Informed Phase II Dose Selection.

A W Krug et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.